Raymond James Financial Inc. Invests $34,000 in Fractyl Health, Inc. (NASDAQ:GUTS)

Raymond James Financial Inc. acquired a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 16,400 shares of the company’s stock, valued at approximately $34,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GUTS. Jane Street Group LLC purchased a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $25,000. Parkside Financial Bank & Trust acquired a new position in shares of Fractyl Health during the fourth quarter worth $27,000. Intech Investment Management LLC acquired a new position in shares of Fractyl Health during the fourth quarter worth $34,000. JPMorgan Chase & Co. increased its holdings in Fractyl Health by 335.4% in the third quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after buying an additional 11,406 shares during the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new stake in Fractyl Health in the fourth quarter valued at $45,000.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $1.54 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. Fractyl Health, Inc. has a one year low of $0.87 and a one year high of $7.89. The firm has a market capitalization of $75.18 million, a P/E ratio of -0.13 and a beta of 0.10. The company’s fifty day moving average is $1.27 and its two-hundred day moving average is $1.75.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.49) EPS for the quarter, hitting the consensus estimate of ($0.49). Analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GUTS has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on shares of Fractyl Health in a research report on Tuesday, April 15th. They issued a “buy” rating and a $12.00 price target for the company. Morgan Stanley reduced their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.